On the basis of therapy, the China Angelman syndrome therapeutics market can be segmented into behavioural therapy, communication therapy, occupational therapy and physiotherapy.
Angelman syndrome can cause a number of behavioural issues, including hyperactivity, aggressive behaviour, sleep disorders, self-injury, and a fascination with water.
Behavioral therapy may be able to help address and cope with these issues.
In communication therapy, speech and language therapists should be involved from an early stage to assess speech development in the child and help identify what approaches will benefit them the most.
Occupational therapy focuses on developing specific skills that can help the children perform daily activities and improve their social interaction.
Physiotherapy can identify problem areas and introduce a tailored exercise plan that can, for example, improve motor skills, strength, posture, and balance.
By Drug Type:
On the basis of drug type, the China Angelman syndrome therapeutics market can be segmented into antiepileptic drugs and anticonvulsant drugs.
Epilepsy is commonly associated with Angelman syndrome, causing seizures, jerky movements, and prolonged periods of unresponsiveness known as nonconvulsive status epilepticus (NCSE). Antiepileptic drugs include Sodium Valproate, Clonazepam and Topiramate are used to treat Angelman syndrome associated epilepsy. Anticonvulsant drugs such as Phenobarbital are used for treatment of Angelman syndrome.
By Distribution Channel:
On the basis of distribution channel, the China Angelman syndrome therapeutics market can be segmented into retail, online and hospital pharmacies. During the forecast period (2020-2028) hospital pharmacies are the key distribution channels as they have a large patient base compared to other healthcare facilities and they also conduct various clinical trials. Second largest distribution channel is retail pharmacies as for the symptomatic treatment drugs are available in retail pharmacies.
Some of the key players in the China Angelman syndrome therapeutics market are Ovid Therapeutics Inc; Hong Kong Angelman Syndrome Foundation (HKASF); H. Lundbeck A/S; Sarepta Therapeutics.
Key players are adapting various strategies such as distribution partnership, collaboration and licensing agreement to increase the product awareness and market share of the product. For instance, Lundbeck and Ovid Therapeutics Announce Exclusive Worldwide Licensing Agreement for Gaboxadol, and it is used for treatment of Angelman syndrome.